

## AGENDA

**Session 1: Wednesday, May 22, 2024**

Co-chairs: Milan Gupta/Rob Hegele

AGENDA		
7:00 PM	<b>Opening Comments</b>	
7:05 PM	<b>Atrial fibrillation – common pitfalls in anticoagulation</b> <i>Describe challenges with anticoagulation in patients with comorbidities</i>	Andrew Ha
7:25 PM	<b>How to diagnose and manage MINOCA (Myocardial Ischemia without obstructive CAD)</b> <i>Identify how to appropriately diagnose and manage MINOCA (Myocardial Ischemia without obstructive CAD)</i>	Tara Sedlak
7:45 PM	<b>CKD: When to use an SGLT2 inhibitor/GLP-1 agonist</b> <i>Select the appropriate treatment for the management of CKD</i>	Kim Connelly
8:05 PM	<b>CKD: When to use Finerenone</b> <i>Examine the clinical decisions for the selection of Finerenone to treat CKD</i>	Jordan Weinstein
8:25 PM	<b>Discussion</b>	
8:55 PM	<b>Closing Comments</b>	

**Session 2: Wednesday, May 29, 2024**

Co-chairs: Milan Gupta/Rob Hegele

AGENDA		
7:00 PM	<b>Opening Comments</b>	
7:05 PM	<b>What every GP should know about heart failure in 2024</b> <i>Describe appropriate management strategies for heart failure</i>	Stephanie Poon
7:25 PM	<b>A practical approach to LDL and TG-related risk management</b> <i>Recognize the importance of lipid-related risk reduction</i>	Robert Hegele
7:45 PM	<b>The post-MI patient – should we liberalize the use of PCSK9 inhibitors and colchicine?</b> <i>Consider the role of PCSK9 inhibitors and colchicine for patients following an MI</i>	Milan Gupta
8:05 PM	<b>I ordered an Lp(a) level – now what?</b> <i>Determine the role of Lp(a) for cardiovascular risk stratification</i>	Michelle O'Donoghue
8:25 PM	<b>Discussion</b>	
8:55 PM	<b>Closing Comments</b>	

**Session 3: Wednesday, June 5, 2024**

Co-chairs: Milan Gupta/Megha Poddar

SPECIAL OBESITY UPDATE		
7:00 PM	<b>Opening Comments</b>	
7:05 PM	<b>Medical nutrition therapy</b> <i>Identify the role of medical nutrition therapy to support the management of obesity</i>	Jennifer Brown
7:25 PM	<b>Non-alcoholic fatty liver disease</b> <i>Develop an effective management strategy for NAFLD that considers potential risks and benefits of therapeutic options</i>	Magnus McLeod
7:45 PM	<b>Semaglutide and CV outcomes in patients with CAD</b> <i>Summarize the role of Semaglutide in reducing CV risk</i>	Milan Gupta
8:05 PM	<b>Emerging treatments for obesity</b> <i>Explore new and future treatments for the management of obesity</i>	Megha Poddar
8:25 PM	<b>Discussion</b>	
8:55 PM	<b>Closing Comments</b>	

## PLANNING COMMITTEE



Co-chair

**Milan Gupta**

MD, FRCPC, FCCS, FCCS, CPC (HC)  
Assistant Professor  
University of Toronto  
Medical Director, Canadian  
Collaborative Research Network  
Brampton, ON



Co-chair


**Robert A. Hegele**

MD, FRCPC, FACP, FAHA, FCAHS  
Director, London Regional Genomics  
Centre; Distinguished University  
Professor of Medicine and  
Biochemistry, University of Western  
Ontario, London, ON



**Christine Palmay**

MD, CCFP  
Western University Schulich School of Medicine  
Physician, Midtown Health & Wellness Clinic  
Toronto, ON



**Anil Maheshwari**

MD, CCFP, DABOM, DABFM  
Executive Health Physician & Medical Director  
Weight & Lifestyle Program Cleveland Clinic  
Canada  
Family Physician & Obesity Program Clinical  
Lead  
Grandview Medical Centre Family Health Team  
Assistant Clinical Professor (Adjunct), McMaster  
University  
Medical Advisor for Canada - Unraveling  
Obesity  
OntarioMD Peer Leader  
Hamilton, ON



**Laura Reardon**

MD, CCFP, ABOM Diplomate  
Medical Director, Lotus Health Clinic Diplomate,  
American Board of  
Obesity Medicine  
Halifax, NS



Watch the recording on  
CCRN website [Here](#)